Boston Scientific adjusts estimated tariff impact by half

Boston Scientific adjusts estimated tariff impact by half

Medtech Giants Adjust Tariff Forecasts, Indicating Positive Outlook for Q2 and Beyond

Several leading medical technology (medtech) companies have revised their expected tariff charge forecasts for 2025, reflecting a softer impact than initially anticipated.

Boston Scientific halved its expected tariff charge from $200 million down to approximately $100 million for the full year, with much of the impact expected in the second half of 2025. This revision came after the company’s Q2 earnings call and reflects reduced costs from previously projected trade tariffs on imports[1].

Johnson & Johnson's medtech business similarly cut its tariff impact forecast to about $200 million, down from an originally estimated several hundred million dollars. This reduction aligns with their broader strategy of mitigating tariff costs through operational adjustments, supported by strong Q2 earnings and raised full-year guidance[1][3].

Intuitive Surgical now expects its tariff impact to be about 100 basis points (1 percentage point) lower than first-quarter estimates for 2025. The company reported a tariff effect of about 60 basis points in Q2 and anticipates the impact will grow slightly each quarter. They also benefit from tariff exemptions on imports from Mexico and Canada under the USMCA trade agreement[2].

The revised forecasts and tariff charge reductions are largely tied to changes in U.S. trade policy, mitigation strategies by companies, and evolving import tariff rates, especially those affecting goods imported from China (subject to 30% tariffs) and other countries (10% tariffs).

Summary Table:

| Company | Revised Tariff Impact Q2 2025 | Original Forecast | Notes | |--------------------|-----------------------------------|---------------------------|-------------------------------------------------| | Boston Scientific | $100 million (full year, Q2 noted) | $200 million (full year) | Tariff hit halved; sales guidance raised | | Johnson & Johnson | $200 million (medtech segment) | Several hundred million | Cut impact by half; operational tariff mitigation| | Intuitive Surgical | ~60 basis points in Q2; 100 bp lower yr forecast | Higher estimates in Q1 | Benefit from USMCA exemptions; tariff impact dynamic |

These companies have adjusted their forecasts during earnings updates in July 2025, signaling a better-than-expected outlook on tariff-related cost pressures for the medtech sector in Q2 and for the rest of 2025[1][2][3].

Boston Scientific's CEO, Mahoney, expressed ambition to be the overall leader in electrophysiology in the future. The company's electrophysiology group grew by 96% year over year to $840 million, and Boston Scientific is growing the use of its Farapulse PFA system in new markets like Japan and China[1]. In fact, Boston Scientific is the "clear market leader" in Japan for pulsed field ablation devices[1].

Johnson & Johnson's electrophysiology business grew by 11% year over year in the second quarter, and the company aims to retain its global market leadership position in the long term, as it created the electrophysiology category[1][3].

There are ongoing uncertainties about tariff policies, as the U.S. government continues to assess trade relations with various countries. However, current data suggest these top medtech firms are managing the risks effectively, maintaining positive sales growth expectations and strategic positioning[4].

1. Boston Scientific, Johnson & Johnson, and Intuitive Surgical have revised their tariff forecasts for 2025, indicating a reduced impact, with some changes expected in Q2.
2. Boston Scientific has lowered its tariff charge forecast for the full year to approximately $100 million, with the Q2 impact taking a significant portion.
3. Johnson & Johnson's medtech business has reduced its tariff impact forecast to about $200 million, down from several hundreds of millions initially.
4. Intuitive Surgical now expects its tariff impact to be about 100 basis points lower than the first-quarter estimates for 2025, partly due to tariff exemptions under the USMCA trade agreement.
5. The reduced tariff impact forecasts are attributed to changes in U.S. trade policy, mitigation strategies, and evolving import tariff rates, particularly affecting goods imported from China and other countries.
6. CEO Mahoney of Boston Scientific aspires to make the company the overall leader in electrophysiology, with the electrophysiology group growing by 96% year over year to $840 million.
7. Johnson & Johnson aims to maintain its global market leadership position in electrophysiology long-term, having created the category.
8. Despite ongoing uncertainties about tariff policies, these leading medtech firms have shown effective risk management, maintaining positive sales growth expectations and strategic positioning.

Read also: